Get the Stockscreener App
13.04
11.36%
1.33
After Hours:
13.01
-0.03
-0.23%
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Arcutis Biotherapeutics (NASDAQ:ARQT) Sets New 52-Week HighTime to Buy? - MarketBeat
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Purchased by Algert Global LLC - MarketBeat
Arcutis Biotherapeutics Submits Roflumilast Cream 0.15% Supplemental NDA to US FDA for Eczema Treatment - Marketscreener.com
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Acquired by Suvretta Capital Management LLC - MarketBeat
Does Arcutis Biotherapeutics (ARQT) Have the Potential to Rally 60.12% as Wall Street Analysts Expect? - MSN
(ARQT) Investment Analysis - Stock Traders Daily
Arcutis Biotherapeutics, Inc. (ARQT) Now Trades Above Golden Cross: Time to Buy? - Zacks Investment Research
Rubric Capital Management LP Grows Holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
There's Reason For Concern Over Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) Massive 32% Price Jump - Simply Wall St
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Position Increased by Jennison Associates LLC - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 20-Day Moving Average - MSN
Bears are Losing Control Over Arcutis Biotherapeutics (ARQT), Here's Why It's a 'Buy' Now - MSN
Arcutis Biotherapeutics SVP sells $17,190 in stock By Investing.com - Investing.com Nigeria
Arcutis Biotherapeutics SVP sells $17,190 in stock - Investing.com India
Arcutis Biotherapeutics, Inc. (ARQT) Recently Broke Out Above the 200-Day Moving Average - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Crossed Above the 50-Day Moving Average: What That Means for Investors - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Wall Street Analysts See a 70.33% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? - MSN
Arcutis Biotherapeutics SVP sells shares worth $712,620 - Investing.com
Arcutis Biotherapeutics SVP sells shares worth $712,620 By Investing.com - Investing.com UK
Arcutis Biotherapeutics: What Lies Ahead (NASDAQ:ARQT) - Seeking Alpha
Long Term Trading Analysis for (ARQT) - Stock Traders Daily
Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up? - Seeking Alpha
Arcutis Biotherapeutics director sells $94,238 in stock By Investing.com - Investing.com Australia
Rubric Capital Management LP's Strategic Acquisition in Arcutis Biotherapeutics Inc - GuruFocus.com
Insider Selling: Director Terrie Curran Sells Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus.com
Arcutis Biotherapeutics director sells $94,238 in stock - Investing.com
Arcutis' ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour - The Manila Times
Arcutis' ZORYVE Wins Glamour's Best Eczema Treatment Award, Targets 26M Patient Market | ARQT Stock News - StockTitan
GSA Capital Partners LLP Has $2.21 Million Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - MarketBeat
Chronic Hand Eczema Pipeline Update 2024: FDA Approvals, - openPR
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call Transcript - Insider Monkey
Arcutis Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Arcutis Biotherapeutics reports robust growth for ZORYVE - Investing.com
Arcutis Biotherapeutics (NASDAQ:ARQT) Earns "Buy" Rating from Needham & Company LLC - MarketBeat
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlig - GuruFocus.com
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ... - Yahoo Finance
Arcutis Biotherapeutics Reports Strong Q3 2024 Results - TipRanks
Morgan Stanley's Strategic Reduction in Arcutis Biotherapeutics Holdings - GuruFocus.com
Arcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings: Revenue Sur - GuruFocus.com
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Arcutis Q3 Revenue Soars 452% to $44.8M, ZORYVE Sales Surge Amid FDA Progress | ARQT Stock News - StockTitan
High Growth Tech Stocks In The United States To Watch - Simply Wall St
Arcutis Biotherapeutics exec sells $43,551 in stock - Investing.com India
Trend Tracker for (ARQT) - Stock Traders Daily
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):